![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-logo.png\"){kind=logo}
<\/p>\n<\/p>\n
Synairgen plc, the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 June 2020.<\/p>\n
Highlights (including post period-end)<\/strong><\/p>\n Operational<\/strong><\/p>\n Richard Marsden, CEO of Synairgen, said:<\/strong> “The first six months of this year have been the most significant in Synairgen’s history. We were delighted to announce positive results from our hospital-based COVID-19 trial in July, and have been working tirelessly on the progression of SNG001 as a potential treatment for COVID-19 patients. With further positive results from our interim analysis of SNG001 in COPD announced in September 2020, we feel well-equipped to realise our strategy of progressing inhaled interferon beta for the treatment of respiratory viruses. I’d like to thank everyone involved in the Company and trials for all their hard work to date.”<\/em><\/p>\n This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596\/2014 (‘MAR’).<\/p>\n For further enquiries, please contact:<\/strong><\/p>\n Synairgen plc<\/strong> finnCap<\/strong> Consilium Strategic Communications (Financial Media and Investor<\/strong> Tags:<\/b> Mary-Jane Elliott, Sue Stuart, Olivia Manser\n
<\/li>\n
<\/li>\n
<\/li>\n
<\/li>\n
<\/li>\n
<\/li>\n
Financial<\/strong><\/p>\n\n
<\/li>\n
<\/li>\n
<\/li>\n
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800<\/p>\n
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500<\/p>\n
Relations)<\/strong>
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700<\/p>\nSee Campaign: <\/strong>http:\/\/consilium-comms.com<\/a>
Contact Information:<\/b>
Mary-Jane Elliott, Sue Stuart, Olivia Manser
\nsynairgen@consilium-comms.com
\nTel: +44 (0) 20 3709 5700<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\nsynairgen@consilium-comms.com
\nTel: +44 (0) 20 3709 5700<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"Synairgen plc, the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 June 2020. Highlights (including post period-end) Operational Positive results from SG016, its double-blind placebo-controlled Phase II trial of SNG001 in hospitalised COVID-19 patients announced in July The Company extended the SG016 Phase II trial … Continue reading Synairgen plc – Interim results for the six months ended 30 June 2020<\/span><\/a> Continue Reading